118652-93-0

Basic information

• Product Name: 2-Propenoyl chloride, 3-(2-methoxyphenyl)-, (E)-
• CAS NO: 118652-93-0
• Molecular Formula: C10H9ClO2
• Molecular Weight: 196.633
• Mol File: 118652-93-0.mol
• Article Data: 25

Chemical Properties

• CAS DataBase Reference: 2-Propenoyl chloride, 3-(2-methoxyphenyl)-, (E)-(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Propenoyl chloride, 3-(2-methoxyphenyl)-, (E)-(118652-93-0)
• EPA Substance Registry System: 2-Propenoyl chloride, 3-(2-methoxyphenyl)-, (E)-(118652-93-0)

Safety Data

• Hazardous Substances Data: 118652-93-0(Hazardous Substances Data)

Upstream product

• 135-02-4 ortho-anisaldehyde 
• 14737-91-8 (Z)-o-methoxycinnamic acid 
• 6099-03-2 3-(2'-methoxyphenyl)propenoic acid 

Downstream Products

• 57259-99-1 1-[3-(2-methoxy-phenyl)-acryloyl]-4-(4-oxo-5-phenyl-4,5-dihydro-oxazol-2-yl)-piperazine 
• 145237-13-4 (Z)-5-(2-Methoxy-phenyl)-3-oxo-2-(triphenyl-λ⁵-phosphanylidene)-pent-4-enoic acid tert-butyl ester 
• 145237-17-8 (Z)-5-(2-Methoxy-phenyl)-3-oxo-2-(triphenyl-λ⁵-phosphanylidene)-pent-4-enoic acid benzyl ester 
• 157603-99-1 (E)-1-((1S,5R,7R)-10,10-Dimethyl-3,3-dioxo-3λ⁶-thia-4-aza-tricyclo[5.2.1.0^1,5]dec-4-yl)-3-(2-methoxy-phenyl)-propenone 
• 84050-30-6 (E)-1-[4-(4-Amino-6,7-dimethoxy-quinazolin-2-yl)-piperazin-1-yl]-3-(2-methoxy-phenyl)-propenone; hydrochloride 
• 1227263-00-4 (E)-N,3-bis(2-methoxyphenyl)acrylamide 
• 1227262-99-8 (E)-3-(2-methoxyphenyl)-N-(3,4,5-trimethoxyphenyl)acrylamide 
• 1333163-06-6 (E)-N-(4-(3-bromophenylamino)quinazolin-6-yl)-3-(2-methoxyphenyl)acrylamide 

Relevant articles and documents

Practical access to fluorescent 2,3-naphthalimide derivatives: Via didehydro-Diels-Alder reaction

A practical and efficient approach for the synthesis of fluorescent 2,3-naphthalimide derivatives has been developed from readily available starting materials via an intramolecular didehydro-Diels-Alder reaction, which proceeded well under room temperature, exhibiting a wide substrate scope and good functional group tolerance. The practicability of this methodology has been verified by one-step synthesis of the environmentally sensitive fluorophore 6-DMN on a gram scale with a shorter time, fewer steps and less waste disposal, and without the utilization of toxic transition metals. The present experimental and computational studies support the crucial role of the propiolimide moiety in the transformation.

Meta-substituted piperlongumine derivatives attenuate inflammation in both RAW264.7 macrophages and a mouse model of colitis

Piperlongumine (PL) has been showed to have multiple pharmacological activities. In this study, we reported the synthesis of three series of PL derivatives, and evaluation of their anti-inflammatory effects in both lipopolysaccharide (LPS)-induced Raw264.7 macrophages and a dextran sulfate sodium (DSS)-induced mouse model of colitis. Our results presented that two meta-substituent containing derivatives 1–3 and 1–6, in which γ-butyrolactam replaced α,β-unsaturated δ-valerolactam ring of PL, displayed low cytotoxicity and effective anti-inflammatory activity. Molecular docking also showed that the meta-substituted derivative, compared with the corresponding ortho- or para-substituted derivative, had significant interactions with the amino acid residues of CD14, which was the core receptors recognizing LPS. In vitro and in vivo studies, 1–3 and 1–6 could inhibit the expression of pro-inflammatory cytokines, and the excessive production of reactive nitrogen species and reactive oxygen species. Oral administration of 100 mg/kg/day of 1–3 or 1–6 alleviated the severity of clinical symptoms of colitis in mice, and significantly reduced the colonic tissue damage to protect the colonic tissue from the DSS-induced colitis. These results suggested that meta-substituted derivatives 1–3 and 1–6 were potential anti-inflammatory agents, which may lead to future pharmaceutical development.

Isoalantolactone derivative, pharmaceutical composition and application thereof

The invention relates to an isoalantolactone derivative, a pharmaceutical composition and application thereof, especially use of the isoalantolactone derivative shown as formula (I) or a salt pharmaceutical compound thereof in preparation of adjuvant drugs treating cancer, a pharmaceutical composition containing a therapeutically effective amount of isoalantolactone derivative (I) or its salt anda pharmaceutically acceptable carrier or a composition with other anticancer drugs.